FDAsafety guidance66% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · AKT Inhibitor
- Sub-indication
- General
Related signal: FDA Acceptance of NDA for Capivasertib by AstraZeneca